| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Quest Diagnostics is teaming up with a Spain-based biotech to bring an advanced colorectal cancer screening blood test to the U.S. Under the new partnership, the Secaucus-headquartered testing provider will work with UDX to develop and seek U.S. Food and Drug Administration premarket approval for a novel “liquid biopsy” blood test to screen for colorectal cancer, the third leading cause of cancer death in the country, according to a Nov. 20 announcement.
For its third annual look-ahead, CLP recently asked a wide range of clinical laboratory experts to look into their professional crystal balls and make their predictions for 2024.
In honor of National Alzheimer’s Awareness Month, held November 2023, Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, delved into some commonly-believed myths about Alzheimer disease and provided his insight on the scientific explanations for these assumptions.
Quest Diagnostics recently launched Quest Mobile™, which the Secaucus-based health care company says will make it easier and more convenient for patients to have a specimen collected for lab testing nationwide. Patients can request an appointment for at-home specimen collection with a trained Quest Mobile phlebotomist for a broad range of laboratory tests in the comfort of their home.
Michael McPhaul, MD, is senior medical director of endocrinology at Quest Diagnostics and editor of the Journal of Investigative Medicine High Impact Case Reports. His work at Quest Diagnostics focuses on the development of new tests for biomarkers of metabolic health to improve prevention, early diagnosis, and monitoring for patients with cardiometabolic health conditions. Here, he discusses advances in insulin resistance testing.